SPA
PACB icon

Sherbrooke Park Advisers’s Pacific Biosciences PACB Stock Holding History

Sherbrooke Park Advisers’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-155,769
Closed -$584K – 1131
2024
Q1 		$584K Buy
+155,769
New +$912K 0.11% 312

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's PACB Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 155,769 shares — an estimated $584K sold.

Sherbrooke Park Advisers first reported a position in PACB in Q1 2024 and held it in 1 quarter. The position peaked at $584K in Q1 2024. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 155,769 Pacific Biosciences shares in Q2 2024, an estimated $584K.
  • Sherbrooke Park Advisers first reported a position in Pacific Biosciences in Q1 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Pacific Biosciences position peaked at $584K in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.